Dr. Doris Fuertinger, Fresenius Medical Care’s Head of Computational Medicine, discusses the use of science-based systemic modeling tools to test a spectrum of hypotheses about the future impact of novel therapeutic interventions on populations with kidney disease.

Generative AI represents a paradigm shift in the landscape of healthcare, offering unprecedented potential to revolutionize patient care, diagnosis, and treatment methodologies. However, amid its promising advancements substantial and daunting risks remain. Dr. Hanjie Zhang, Senior Director of...

Dr. Giovanni Strippoli, Professor of Nephrology at University of Bari, Italy, discusses how the CONVINCE study results will contribute to reaching a higher level of certainty regarding the comparative efficacy of hemodiafiltration (HDF) versus HD in people with end-stage kidney disease.